Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders
NCT06056297Phase 3Recruiting
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Jun 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in neutropenia comparing Mavorixafor with Placebo (2 arms). Primary endpoints: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) at 52 weeks and Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) Response at 52 weeks. Started Jun 2024; status: recruiting.
02
Drugs
mavorixafor
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT06056297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056297.